EUVIMEDEUVIMED entdecken
Crossref

Cognition Assessment with ICOPE-Monitor: Identifying Candidates for Novel Therapies

Emmanuel Gonzalez-Bautista, Maria Soto, Marie Fourteau, Caroline Berbon, Bruno Vellas, Julien Delrieu, Davide Angioni

Journal of the American Medical Directors Association · 2025

DOI: 10.1016/j.jamda.2024.105483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Medical Directors Association, 2025. Verfasst von Emmanuel Gonzalez-Bautista und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Research Alzheimer's Disease Center (CMRR), CHU Toulouse, IHU HealthAge, Toulouse, France; Maintain Aging Research Team, Centre d'Epidém…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Neuropsychological Tests, Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: European Commission, Agence Nationale de la Recherche, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To describe the clinical performance of the cognition battery on Step 1 (CogStep1) as a screening tool to detect (1) individuals with objective cognitive impairment regardless of their Mini-Mental State Exam (MMSE) score, and specifically (2) to identify patients who could potentially benefit from anti-amyloid treatments. It was hypothesized that CogStep1 was sensitive enough to identify individuals with mild stages of cognitive deterioration compared with a comprehensive neuropsychological and clinical evaluation. DESIGN: Cross-sectional study. SETTING AND PARTICIPANTS: Patients aged 60 and older referred to the Toulouse Memory Clinic. METHODS: Participants underwent a comprehensive neuropsychological and clinical evaluation and were also screened with the integrated care in older people (ICOPE)-monitor Step 1 by trained health professionals a maximum of 6 months before their memory consultation. Objective cognitive impairment was defined as mild cognitive impairment (MCI) or dementia, according to National Institute on Aging and the Alzheimer's Association criteria. A positive CogStep1 screening was considered if people had at least 1 mistake in the 3-word recall or the time orientation (weekday, month, year). Sensitivity, specificity, area under the receiver operating characteristic curve (AUROC), positive predictive value (PPV), and negative predictive value (NPV) were estimated. RESULTS: Among the 352 participants [54.8% women, mean age 76.5 (SD 6.7)], 78.1% had a positive screening for CogStep1, and 75.6% had objective cognitive impairment. The clinimetric properties of CogStep1 to detect objective cognitive impairment (vs those without) were sensitivity = 87.0 (95% CI, 82.3-90.8), specificity = 48.8 (95% CI, 37.9-59.9), AUROC = 0.68 (95% CI, 0.62-0.74), PPV = 83.8 (95% CI, 78.8-87.9), and NPV = 55.3 (95% CI, 43.4-66.7). We found similar values among individuals with MCI or mild dementia who could be potential users of new anti-amyloid drugs (MMSE score ≥ 20 or 22). CONCLUSION AND IMPLICATIONS: CogStep1 demonstrated good sensitivity and PPV to identify objective cognitive impairment among older people referred to a memory clinic. Achieving excellent sensitivity and specificity values is challenging for a very short test. However, CogStep1 proved useful for risk-stratifying patients who can benefit from further cognitive assessment, biomarker measurements, and therapeutic management, especially in the context of new anti-amyloid therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionNeuropsychological TestsDementiaHumansAgedFemaleMaleCross-Sectional StudiesMiddle AgedAged, 80 and overSensitivity and Specificity

Stichwörter der Autor:innen

ICOPEanti-amyloidclinimetricsmemory clinics

Autor:innen und Institutionen

  • Clinical and Research Alzheimer's Disease Center (CMRR), CHU Toulouse, IHU HealthAge, Toulouse, France; Maintain Aging Research Team, Centre d'Epidémiologie et de Recherche en santé des POPulations, Université de Toulou…
  • Equipe Régionale Vieillissement et Prévention de la Dépendance (ERVPD), IHU HealthAge, Toulouse, France.
  • Maintain Aging Research Team, Centre d'Epidémiologie et de Recherche en santé des POPulations, Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France; Equipe Régionale Vieillissement et Prévention de…

Förderung

  • European Commission
  • Agence Nationale de la Recherche
  • European Regional Development Fund

Zitieren

APA

Gonzalez-Bautista, E., Soto, M., Fourteau, M., Berbon, C., Vellas, B., Delrieu, J., & Angioni, D. (2025). Cognition Assessment with ICOPE-Monitor: Identifying Candidates for Novel Therapies. Journal of the American Medical Directors Association. https://doi.org/10.1016/j.jamda.2024.105483

Vancouver

Gonzalez-Bautista E, Soto M, Fourteau M, Berbon C, Vellas B, Delrieu J, et al. Cognition Assessment with ICOPE-Monitor: Identifying Candidates for Novel Therapies. Journal of the American Medical Directors Association. 2025. doi:10.1016/j.jamda.2024.105483

BibTeX
@article{GonzalezBautista2025,
  author = {Gonzalez-Bautista, Emmanuel and Soto, Maria and Fourteau, Marie and Berbon, Caroline and Vellas, Bruno and Delrieu, Julien and Angioni, Davide},
  title = {Cognition Assessment with ICOPE-Monitor: Identifying Candidates for Novel Therapies},
  journal = {Journal of the American Medical Directors Association},
  year = {2025},
  doi = {10.1016/j.jamda.2024.105483}
}
Kostenlos starten →